Waltham, MA-based PerkinElmer (NYSE: [[ticker:PKI]]) has successfully completed its tender offer for Cambridge’s ViaCell (NASDAQ: [[ticker:VIAC]]), the company announced today. The company purchased more than 90% of ViaCell’s outstanding shares in the transaction, which is part of a $300 million acquisition announced early in October. PerkinElmer expects to complete the merger “promptly.”
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
